These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody. Rosenblum MG; Murray JL; Stuckey S; Newman RA; Chaney S; Khokhar AR Cancer Chemother Pharmacol; 1990; 25(6):405-10. PubMed ID: 2311167 [TBL] [Abstract][Full Text] [Related]
3. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Mujoo K; Watanabe M; Khokhar AR; Siddik ZH Prostate; 2005 Jan; 62(1):91-100. PubMed ID: 15389812 [TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Siddik ZH; al-Baker S; Thai G; Khokhar AR Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929 [TBL] [Abstract][Full Text] [Related]
6. Antibodies against (1R,2R)-cyclohexanediamineplatinum(II)-DNA adduct recognize the conformational differences of isomeric analogues of cyclohexanediamine. Yamada H; Kato T; Hirose J; Inagaki K; Noji M; Kidani Y Biochim Biophys Acta; 1990 Jul; 1049(3):298-302. PubMed ID: 2383586 [TBL] [Abstract][Full Text] [Related]
7. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
8. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719 [TBL] [Abstract][Full Text] [Related]
9. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Mauldin SK; Gibbons G; Wyrick SD; Chaney SG Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241 [TBL] [Abstract][Full Text] [Related]
10. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line. Mauldin SK; Husain I; Sancar A; Chaney SG Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013 [TBL] [Abstract][Full Text] [Related]
11. The inhibition of P338 lymphocytic leukemia DNA polymerase alpha activity by cis-diamminedichloroplatinum(II) and related derivatives. Oswald CB; Hall IH Anticancer Res; 1989; 9(4):915-22. PubMed ID: 2817817 [TBL] [Abstract][Full Text] [Related]
12. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O. Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801 [TBL] [Abstract][Full Text] [Related]
13. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629 [TBL] [Abstract][Full Text] [Related]
15. Luminescent amidate-bridged one-dimensional platinum(II)-thallium(I) coordination polymers assembled via metallophilic attraction. Chen W; Liu F; Xu D; Matsumoto K; Kishi S; Kato M Inorg Chem; 2006 Jul; 45(14):5552-60. PubMed ID: 16813418 [TBL] [Abstract][Full Text] [Related]
16. Toxicity and anti-tumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles. Khokhar AR; Al-Baker S; Perez-Soler R Anticancer Drug Des; 1988 Dec; 3(3):177-84. PubMed ID: 3207465 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Luo FR; Wyrick SD; Chaney SG Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). Sundquist WI; Lippard SJ; Stollar BD Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320 [TBL] [Abstract][Full Text] [Related]
19. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Yoshida M; Khokhar AR; Siddik ZH Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968 [TBL] [Abstract][Full Text] [Related]
20. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]